Between the Christmas lows, when my interview was published and yesterday's Q4/18 results, Protagonist (PTGX) had a strong run for a ~50% return. Investors were probably anticipating good news about the PTG-200 development partnership with Janssen - which once again didn't arrive.
PTG-200 has successfully concluded a phase 1 trial in Australia and Protagonist expects Janssen to file a U.S. IND application for the treatment of Crohn's disease. However, it has been expecting a filing for many months now and the news vacuum around this asset is quite frightening.
Here is an